The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Experts

16 hours ago · 5 analysts have shared their evaluations of Ionis Pharmaceuticals IONS during the recent three months, expressing a mix of bullish and bearish perspectives. The following table …

$63.83
OFF

12 Analysts Have This To Say About Ionis Pharmaceuticals

2 weeks from now

Aug 2, 2024 · Analysts have recently evaluated Ionis Pharmaceuticals and provided 12-month price targets. The average target is $63.83, accompanied by a high estimate of $82.00 and a …

nasdaq.com

$51.00
OFF

Analysts Conflicted On These Healthcare Names: Ionis …

2 weeks from now

Dec 23, 2024 · Barclays analyst Gena Wang maintained a Hold rating on Ionis Pharmaceuticals today and set a price target of $51.00. The company’s shares closed last Friday at $35.63, …

businessinsider.com

4%
OFF

Ionis Pharmaceuticals Beats On Revenue | The Motley Fool

2 weeks from now

Nov 6, 2024 · Ionis Pharmaceuticals exceeded revenue estimates by 3.4%, reporting $134 million against a $129.57 million expectation. Spinraza royalties decreased by $10 million year over …

fool.com

$55.00
OFF

Ionis Pharmaceuticals: Hold Rating Amid Uncertainty In Future …

2 weeks from now

3 days ago · Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), retaining the price target of $55.00. Discover …

businessinsider.com

$61.08
OFF

Deep Dive Into Ionis Pharmaceuticals Stock: Analyst ... - Nasdaq

2 weeks from now

Sep 26, 2024 · Analysts have recently evaluated Ionis Pharmaceuticals and provided 12-month price targets. The average target is $61.08, accompanied by a high estimate of $75.00 and a …

nasdaq.com

$62
OFF

Where Ionis Pharmaceuticals Stands With Analysts - Nasdaq

2 weeks from now

Nov 7, 2024 · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $62.5, a high estimate of $70.00, and a low estimate of $55.00.

nasdaq.com

$15
OFF

The Analyst Verdict: Eton Pharmaceuticals In The Eyes Of 5 Experts

2 weeks from now

Jan 8, 2025 · Analysts have set 12-month price targets for Eton Pharmaceuticals, revealing an average target of $15.2, a high estimate of $18.00, and a low estimate of $11.00.

nasdaq.com

FAQs about The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Experts Coupon?

How much debt does Ionis Pharmaceuticals have?

Debt Management: Ionis Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 4.87. This suggests the company carries a substantial amount of debt, posing potential financial challenges. What Are Analyst Ratings? ...

Does Ionis Pharmaceuticals have a high debt-to-equity ratio?

Debt Management: Ionis Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 4.6. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage. Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. ...

How do analysts evaluate Ionis Pharmaceuticals (Ionis) stock?

Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future value. ...

Does Ionis Pharmaceuticals have a good Roa?

With an ROA of -4.99%, the company may need to address challenges in generating satisfactory returns from its assets. Debt Management: Ionis Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 4.6. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage. ...

Is Ionis Pharmaceuticals (ions) a good stock to buy?

Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), retaining the price target of $55.00. Michael Ulz has given his Hold rating due to a combination of factors related to Ionis Pharmaceuticals’ current status and future prospects. ...

Why do analysts'maintain' or 'raise' their stance on Ionis Pharmaceuticals?

Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ionis Pharmaceuticals. ...